Table 4.
Colistin + levofloxacin group (n = 120), death/total number of cases (%) | Meropenem + levofloxacin group (n = 112), death/total number of cases (%) | p value | |
---|---|---|---|
VAP caused by A. baumannii, P. aeruginosa, and K. pneumoniae (n = 79) | 40 (48.8) | 39 (52) | 0.811 |
MIC distribution | |||
Meropenem MIC | |||
≤ 2 mg/l—susceptible | 4/16 (25) | 5/18 (27.8) | 0.885 |
> 2–8 mg/l—intermediate | 0/4 (0) | 0/5 (0) | – |
> 8 mg/l—resistant | 5/20 (25) | 6/16 (37.5) | 0.419 |
Colistin MIC | |||
≤ 2 mg/l—susceptible | 9/35 (25.7) | 8/32 (25) | 0.947 |
> 2 mg/l—resistant | 0/5 (0) | 3/7 (42.9) | 0.091 |
MIC minimum inhibitory concentration, VAP ventilator-associated pneumonia